US Quickly Seeks COVID-19 Vaccine.
“Phase 1 of the clinical trial to evaluate an investigational vaccine designed for coronavirus disease 2019 (COVID-19) has begun at the Kaiser Permanente Washington Health Research Institute in Seattle (KPWHRI),” the NIH said, They finance this project through one of its centers, the National Institute of Allergy and Infectious Diseases (NIAID).
Experts administered the vaccine on Monday to the first of 45 volunteers, all of them healthy adults between the ages of 18 and 55, who will take part in this experiment over six weeks.
The vaccine is called RNA-1273 and has been developed by scientists from NIAID and the modern biotechnology company.
The different doses of this experimental vaccine are being evaluated in this study for safety and its ability to induce an immune response in volunteers.
NIAID Director Anthony Fauci explained in the note that “finding a safe and effective vaccine to prevent SARS-CoV-2 infection is an urgent public health priority.”
Currently there is no vaccine approved by health authorities to prevent infection.